Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNA-051 for Prevention of COVID-19
NCT05118763Phase 2Withdrawn
- Sponsor
- ENA Respiratory
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of INNA-051 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by ENA Respiratory. Primary endpoints: Incidence of symptomatic RT-PCR confirmed SARS-CoV-2 infection at Day 14 and Safety and tolerability of INNA-051 at Day 42. Planned start Mar 2022; status: withdrawn.
02
Drugs
INNA-051
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05118763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118763.